Browse the evidence

Power over food production and consumption is distributed unequally, favoring large corporations.

This suggests that advocacy for equitable food policies is necessary.

The evidence does not support the supplementation with phosphatidic acid (PA) to increase performance or improve body composition in young or elderly men.

Practitioners should be cautious in recommending PA as an anabolic supplement due to lack of supporting evidence.

Three studies suggested no effect of phosphatidic acid on lean body mass.

The lack of effect on lean body mass suggests PA may not be a viable supplement for muscle gain.

In women with type 2 diabetes, cardiovascular autonomic neuropathy (CAN) is significantly associated with an increased risk of all-cause mortality (CAN1: HR 1.64, CAN2: HR 1.58, CAN3: HR 1.78) and cardiovascular disease mortality (CAN1: HR 2.25, CAN2: HR 2.22, CAN3: HR 3.31).

Healthcare providers should prioritize monitoring CAN in women with type 2 diabetes to mitigate mortality risk.

Cardiovascular autonomic neuropathy (CAN) is not significantly associated with mortality in men with type 2 diabetes.

Men with type 2 diabetes may require different monitoring strategies for mortality risk compared to women.

There was no association found between weight loss and improvement in FEV1 or FVC.

Weight loss from GLP-1 therapies may not lead to improvements in lung function, indicating the need for further investigation.

Side effects were common and led to discontinuation of the medication in 18.5% of patients.

Clinicians should monitor for side effects in patients on GLP-1 therapies, as they may affect treatment adherence.

GPR75 is an attractive pharmacological target for the treatment of obesity and metabolic syndrome.

Targeting GPR75 may lead to more effective treatments for obesity and metabolic syndrome.

Gene targeting of GPR75 is more effective than current pharmacologic therapies without the known side effects.

Gene targeting may provide a safer and more effective alternative to current obesity treatments.

GPR75 and its ligand promote hypertension, inflammation, obesity, and insulin resistance.

Understanding the role of GPR75 can inform strategies to mitigate obesity-related health risks.

The annual additional direct medical cost for Semaglutide was USD 4,086.82.

Practitioners should consider the high cost of Semaglutide when discussing treatment options.

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

Semaglutide is projected to increase annual health care spending by $23 billion.

Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.

The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.

Practitioners should consider these barriers when recommending injectable therapies for obesity.

Future pharmacotherapeutic options, including combination therapies and gene therapy, may improve outcomes for patients with genetic obesity disorders.

Practitioners should stay informed about emerging therapies that may enhance treatment for genetic obesity.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.

The healthcare situation for people with obesity in Germany is deficient.

Healthcare providers should recognize the deficiencies in the current obesity care system.

There were previously no legal frameworks for guideline-based care for people with obesity.

Legislators need to establish legal frameworks to support guideline-based obesity care.

Carbon monoxide (CO) has potential therapeutic applications in obesity treatment.

Practitioners might explore CO-based therapies as innovative options for obesity management.

HEC-CG115 has an optimal safety profile with a no observed adverse effect level of 3 mg/kg.

HEC-CG115 appears to be a safe option for therapeutic use.

Obesity is a chronic metabolic disorder that shares underlying pathophysiology with type 2 diabetes mellitus, cardiovascular disease, and diabetic cardiomyopathy.

Understanding the metabolic links can help in developing targeted interventions for obesity and related diseases.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

Ingestion of 20 g and 40 g of soy protein isolate does not stimulate increased rates of myofibrillar protein synthesis (MPS) under resting conditions in the elderly.

Soy protein isolate may not be effective for increasing muscle protein synthesis in elderly individuals.

There was no significant effect of the intervention on daily steps, daily activity energy expenditure, or moderate-to-vigorous physical activity compared to the control group.

Practitioners should note that the program did not significantly increase physical activity levels.